^
    16h
    A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyping (clinicaltrials.gov)
    P3, N=156, Not yet recruiting, Ruijin Hospital
    New P3 trial
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    doxorubicin hydrochloride • cyclophosphamide
    3d
    The molecular pathogenesis of Epstein-Barr virus-associated B-cell lymphoproliferative disorders: a scoping review. (PubMed, Expert Rev Hematol)
    Amplification of 9p24.1, causing PD-L1 overexpression, plays a significant role in EBV-positive DLBCL and EBV-positive cHL, whereas EBVMCU, DLBCL-CI, FA-DLBCL, and LyG primarily depend on an (local) immunosuppressive condition. In conclusion, the molecular pathogenesis of EBV LPD is less reliant on driver mutations and instead rely on EBV latent genes and immune evasion; both factors provide promising targets for future therapy.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    PD-L1 overexpression
    3d
    miR-193-5p, miR-1307-5p, and miR-671-5p: Potential biomarkers for chemoresistance in diffuse large B-cell lymphoma. (PubMed, Indian J Med Res)
    In vitro proteomics showed their impact on key oncogenic pathways, revealing significant enrichment of replication and transcription-related proteins. Interpretation and conclusions The expression of miR-193b-5p, miR-1307-5p, and miR-671-5p miRNAs in diffuse large B-cell lymphoma tissues may serve as predictive biomarkers.
    Review • Journal
    |
    MIR193B (MicroRNA 193b) • MIR671 (MicroRNA 671)
    4d
    Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies (clinicaltrials.gov)
    P1, N=42, Recruiting, Medical College of Wisconsin | Not yet recruiting --> Recruiting | Trial completion date: Jul 2028 --> Jul 2029 | Trial primary completion date: Jan 2027 --> Jan 2028
    Enrollment open • Trial completion date • Trial primary completion date • First-in-human
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 expression
    |
    CD30 biAb-AATC • Leukine (sargramostim)
    4d
    A051901: Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma (clinicaltrials.gov)
    P1, N=47, Recruiting, National Cancer Institute (NCI) | Trial completion date: May 2026 --> Apr 2027 | Trial primary completion date: May 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • Rituxan (rituximab) • lenalidomide • methotrexate • Truxima (rituximab-abbs) • ABP 206 (nivolumab biosimilar) • Mabtas (rituximab biosimilar) • methotrexate IV
    4d
    Clinical Characteristics and Outcome of Diffuse Large B-Cell Lymphoma: Real-World Data From Saudi Arabia. (PubMed, JCO Glob Oncol)
    This study provides valuable real-world insight into the clinical landscape of DLBCL in Saudi Arabia. Overall outcomes are consistent with international data, although older age and comorbidities remain associated with poorer prognosis. As advanced therapies such as chimeric antigen receptor T-cell therapy and bispecific antibodies become more available, further improvements in survival are expected. These findings underscore the need for a national lymphoma registry and continued investment in research infrastructure to guide evidence-based, personalized care.
    Retrospective data • Journal • Real-world evidence
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone
    4d
    IL-16 in Vitreoretinal Lymphoma: First Vitreous Detection and a Preliminary Longitudinal Observation. (PubMed, Ocul Immunol Inflamm)
    A patient with biopsy-proven VRL underwent longitudinal vitreous cytokine analysis during intravitreal methotrexate (MTX) and dexamethasone (DEX) therapy. Co-expression of IL-10 and IL-May 16, reflect a dynamic interaction between lymphoma cells and the TME, contributing to immune modulation and treatment resistance. Longitudinal IL-16 monitoring may provide additional insight into disease activity and therapeutic response; however, this requires validation in larger VRL cohorts, ideally including inflammatory controls.
    Journal
    |
    IL6 (Interleukin 6) • IL10 (Interleukin 10) • IL16 (Interleukin 16)
    |
    methotrexate • dexamethasone
    4d
    AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=45, Completed, Artiva Biotherapeutics, Inc. | Active, not recruiting --> Completed | Trial primary completion date: Aug 2024 --> Oct 2025
    Trial completion • Trial primary completion date
    |
    Rituxan (rituximab) • cyclophosphamide • bendamustine • fludarabine IV • AlloNK (GCC4001)
    4d
    CYTB323A12101: Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL (clinicaltrials.gov)
    P1/2, N=217, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: May 2028 --> Jun 2027
    Trial completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CD19 positive
    |
    Imbruvica (ibrutinib) • rapcabtagene autoleucel (YTB323)
    5d
    Isoform-Specific Functions of p73 Drive Survival and Chemoresistance in Diffuse Large B-Cell Lymphoma. (PubMed, bioRxiv)
    Functional studies in DLBCL cell lines further confirmed that TAp73 enhances sensitivity to serum deprivation and doxorubicin, whereas ΔNp73 overexpression promotes survival and chemoresistance...Functional studies showed TAp73 sensitizes DLBCL cells to stress and chemotherapy, while ΔNp73 enhances resistance. These findings highlight ΔNp73 as a potential biomarker and therapeutic target in DLBCL.
    Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • CASP3 (Caspase 3) • TP73 (Tumor Protein P73)
    |
    doxorubicin hydrochloride
    5d
    DEL-MRD-CHID: Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission (clinicaltrials.gov)
    P2, N=69, Not yet recruiting, Rong Tao
    New P2 trial • Minimal residual disease • Circulating tumor DNA
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Epidaza (chidamide)